Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
about
Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomesPractical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial reviewRelationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failureViral quasispecies evolutionPrevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE studyAdded value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjectsPrevalence and impact of minority variant drug resistance mutations in primary HIV-1 infectionMinor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failureReappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infectionStanding genetic variation and the evolution of drug resistance in HIVHighly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in JapanFirst line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter studyPrevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failurePrevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, ChinaContribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapyMinority drug-resistant HIV-1 variants in treatment naïve East-African and Caucasian patients detected by allele-specific real-time PCRComparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical TransmissionHow Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health ImpactPrevalence of Primary HIV Drug Resistance in Thailand Detected by Short Reverse Transcriptase Genotypic Resistance AssayAn Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 QuasispeciesSensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015.A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1Minority variants of drug-resistant HIV.Prevalence and virologic consequences of transmitted HIV-1 drug resistance in UgandaCharacterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencingIncreasing transfers-out from an antiretroviral treatment service in South Africa: patient characteristics and rates of virological non-suppression.Next generation sequencing improves detection of drug resistance mutations in infants after PMTCT failure.Improved detection of rare HIV-1 variants using 454 pyrosequencing.Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing.Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialDetection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants.Clinical management of HIV drug resistance.Ongoing HIV Transmission and the HIV Care Continuum in North Carolina.Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysisPrevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010.HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument.Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.Quasispecies Analyses of the HIV-1 Near-full-length Genome With Illumina MiSeq.
P2860
Q26851997-4BFBB3E7-D154-4D1E-89CA-5B1431D5F148Q26853055-76D213DF-7F7D-4FC7-B904-7504EB395D1EQ27003431-CC2F8793-862D-4791-9BD5-2551D8D92C39Q27013917-F2D8C29A-0DD9-40B2-817F-DED76864EBE4Q28474221-38016B72-20CC-4D50-8E5C-6826C7645A6AQ28478134-2B3325B4-D0B0-4393-83A6-718C44C91FC4Q28478459-81BFBAE6-0E76-461C-8093-7D06319B692EQ28478779-BF3FD17D-189F-4807-A439-485F55E436E9Q28478934-5D6AA464-3EC3-4BD3-957C-1D0EF6288FB5Q28484153-05B52BD3-EDAF-4103-8B61-CF513B02F83AQ28537608-58B259B5-DAE3-4944-A9B3-47C9CBEBB46FQ28538326-FF57ECDA-64CD-41ED-997A-D62CC6CA62BBQ28539186-4D2637B7-7B8A-4601-AB78-61B16A930DA8Q28539368-3B8763BB-3E3D-4604-A318-128D571AD144Q28541754-5442DC3F-A399-417F-84E4-22E82CFFFF7EQ28543986-3DC8D7C7-925A-4E77-98C7-BE0396D20C5CQ28550310-F0AB5CB4-9525-4CFF-AAEB-0ADEFCD9FF2FQ28552455-C368F81A-40D4-4C16-BC90-889DBFD2AE2AQ28553024-847A9394-C55D-4CD0-9C7E-44DCC830956FQ28554999-D2391EAF-73C2-41E2-85C0-FC732479564BQ33622927-7C5A52C0-3807-43C4-B60F-DFF6ED0FAAC8Q33634625-17F0F075-05CE-4AEC-AF09-E78B8BBC9733Q33927293-12E7CD55-CFBE-4741-BCCB-007FE15697B2Q34047780-3CAF512E-DC6E-4402-AC17-A269119B21B7Q34116836-C32463DF-7BA9-4943-8D21-68CF6C2CA9E6Q34567556-B75EB492-1AD5-42BD-827F-B3257BFD9E70Q34614542-5FA7C237-4AF4-4D18-9898-5527E745623EQ34785616-0C4998E2-6DC7-46DA-8F96-C455313FD7D5Q35009489-B99C2C55-E9D0-484E-8C00-66544AE2AB9FQ35056873-D270ABD8-94D8-4F83-BAC1-0539487E4AFDQ35124860-0050ACF4-C180-4B51-9EEB-29BB36F18EF3Q35140450-D206A31B-BF25-4695-B1B0-2D57195CFA7AQ35261045-EFF4ADDB-C997-46CA-932B-80422EFBA4EAQ35652703-A343983D-478C-465D-8EE4-72C54227A5C6Q35694729-2CF458FD-7219-404A-BA48-14FD62E492CFQ35887051-11E71846-F773-4B53-A915-8D022095B7CAQ35944787-529F443F-30A8-497F-9FC7-986FAE738C08Q36158371-B73BDC79-86B9-4F06-B75D-DC8CCB954041Q36186007-D6547E62-88A3-417D-8DB6-750DE16CBFB0Q36271817-A04106BC-637E-4C63-953C-53CC04A99B9F
P2860
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pre-existing minority drug-res ...... iretroviral treatment failure.
@ast
Pre-existing minority drug-res ...... iretroviral treatment failure.
@en
type
label
Pre-existing minority drug-res ...... iretroviral treatment failure.
@ast
Pre-existing minority drug-res ...... iretroviral treatment failure.
@en
prefLabel
Pre-existing minority drug-res ...... iretroviral treatment failure.
@ast
Pre-existing minority drug-res ...... iretroviral treatment failure.
@en
P2093
P2860
P356
P1476
Pre-existing minority drug-res ...... iretroviral treatment failure.
@en
P2093
AIDS Clinical Trials Group (ACTG) A5095 Study Team
Bruce R Schackman
Cecilia Shikuma
Christina M Lalama
Daniel R Kuritzkes
Francoise Giguel
Heather J Ribaudo
Richard T D'Aquila
Roger Paredes
Roy M Gulick
P2860
P304
P356
10.1086/650543
P407
P577
2010-03-01T00:00:00Z